Descripción del proyecto
El ejercicio como medio preventivo de la recurrencia de tumores metastásicos en pacientes con cáncer colorrectal
El cáncer colorrectal (CCR) es el segundo tipo de cáncer más común en Europa y causa la muerte de casi doscientos treinta mil europeos cada año. Alrededor del 30 % de los pacientes con CCR desarrollan metástasis hepáticas, lo cual constituye la principal causa de muerte entre esta población de pacientes. Dado que se ha demostrado que el ejercicio tiene efectos antineoplásicos e inhibe el crecimiento tumoral en modelos animales, la actividad física podría ser un tratamiento complementario excelente junto con el tratamiento antineoplásico farmacológico. El proyecto POET-mCRC, financiado con fondos europeos, tiene como objetivo investigar si el ejercicio a largo plazo puede prevenir o retrasar la recurrencia de la metástasis en pacientes con CCR. Además, pretende identificar la dosis óptima de ejercicio necesaria para obtener estos efectos beneficiosos.
Objetivo
Every year nearly 228,000 individuals die from colorectal cancer (CRC) in Europe, the second most common cancer in Europe. Around 30% of the CRC patients develop liver metastases and these are the main cause of death. Removal of liver metastatic tumors is the primary treatment method for CRC, however, 50-75% of the patients experience a relapse of the metastases within two years, rendering adjunct treatment strategies necessary for these patients.
Preclinical work has demonstrated that exercise exerts anti-tumor effects as it is indeed able to inhibit tumor growth. Thus, exercise constitutes an excellent candidate as a complementary to the pharmacological treatment approach for CRC metastatic patients (mCRC).
My primary aim is to investigate the effects of chronic exercise on tumor recurrence after liver metastasis removal. Secondary aims are to identify the “optimal dose” of exercise to obtain the largest beneficial effect and explore the changes on circulating tumor DNA (ctDNA) as a marker of disease progression. I hypothesize that exercise training will delay or ameliorate disease recurrence in mCRC patients.
Patients will be randomized to 3 groups: control, group 1(300 min/week), group 2 (150 min/week) of combined aerobic and strength exercise training for 6 months. Study endpoints will be tumor recurrence, inflammation and immune markers, physiological adaptations and ctDNA changes.
The outcomes will provide essential knowledge about how to optimize the guidelines for exercise prescription as part of the treatment plan for mCRC patients.
The fellowship will be vital for my reintegration into academia and for me to evolve as a lead researcher. It also constitutes an ideal means of knowledge transfer between myself and the host organization as I will gain knowledge in the oncology area and advance my skills in molecular biology techniques while I convey my experience in dose-response methodology and the conduct of large-scale human exercise trials.
Ámbito científico
Programa(s)
Régimen de financiación
MSCA-IF-EF-CAR - CAR – Career Restart panelCoordinador
3400 Hillerod
Dinamarca